Cutaneous Adverse Effects of Hormonal and HER2-Targeted Therapies in Breast Cancer Patients: A Case Series.

BACKGROUND

Aromatase inhibitors (AIs) and anti-HER2 therapies improve breast cancer survival, but dermatologic adverse events (dAEs) are underrecognized despite affecting quality of life and adherence.

METHODS

We report 4 cases of cutaneous toxicity from AIs or HER2-targeted agents, detailing presentation, management, and outcomes.

RESULTS

Three patients developed acneiform eruptions: one after starting letrozole, resolving on discontinuation, and 2 on trastuzumab/pertuzumab requiring isotretinoin after failing topical/antibiotic therapy. A fourth developed lichen planus pigmentosus six months into anastrozole chemoprevention, with limited response to topicals and treatment cessation due to psychosocial distress.

CONCLUSION

Acneiform eruptions may occur with both HER2 blockade and AIs, while pigmentary disorders may represent a novel AI toxicity. Prompt recognition and targeted care may facilitate cancer treatment continuation. &nbsp.